These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 25612136

  • 1. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
    Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N.
    PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
    [Abstract] [Full Text] [Related]

  • 2. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, Bunge K, Ramjee G, Nair G, Palanee-Phillips T, Selepe P, van der Straten A, Parikh UM, Gomez K, Piper JM, Watts DH, Marrazzo JM, VOICE Study Team.
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [Abstract] [Full Text] [Related]

  • 3. Hormonal contraception and the risk of HIV acquisition among women in South Africa.
    Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, Patel S, Ahmed K, Ramjee G, Friedland B, Lahteenmaki P.
    AIDS; 2012 Feb 20; 26(4):497-504. PubMed ID: 22156973
    [Abstract] [Full Text] [Related]

  • 4. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa.
    Myer L, Denny L, Wright TC, Kuhn L.
    Int J Epidemiol; 2007 Feb 20; 36(1):166-74. PubMed ID: 17175547
    [Abstract] [Full Text] [Related]

  • 5. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
    Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, Hannaford P, Turner AN.
    Contraception; 2014 Oct 20; 90(4):360-90. PubMed ID: 25183264
    [Abstract] [Full Text] [Related]

  • 6. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.
    Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, Nunn A, Chisembele M, Ramjee G, Rees H, McCormack S.
    Hum Reprod; 2014 Aug 20; 29(8):1810-7. PubMed ID: 24838704
    [Abstract] [Full Text] [Related]

  • 7. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
    Grabowski MK, Gray RH, Makumbi F, Kagaayi J, Redd AD, Kigozi G, Reynolds SJ, Nalugoda F, Lutalo T, Wawer MJ, Serwadda D, Quinn TC, Tobian AAR.
    Lancet Glob Health; 2015 Aug 20; 3(8):e478-e486. PubMed ID: 26094162
    [Abstract] [Full Text] [Related]

  • 8. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
    Singata-Madliki M, Smit J, Beksinska M, Balakrishna Y, Avenant C, Beesham I, Seocharan I, Batting J, Hapgood JP, Hofmeyr GJ.
    PLoS One; 2024 Aug 20; 19(3):e0295764. PubMed ID: 38530848
    [Abstract] [Full Text] [Related]

  • 9. Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data.
    Ralph LJ, Gollub EL, Jones HE.
    Curr Opin Obstet Gynecol; 2015 Dec 20; 27(6):487-95. PubMed ID: 26536211
    [Abstract] [Full Text] [Related]

  • 10. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
    Jain AK.
    Contraception; 2012 Dec 20; 86(6):645-52. PubMed ID: 22541635
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis.
    Dabee S, Tanko RF, Brown BP, Bunjun R, Balle C, Feng C, Konstantinus IN, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Gill K, Baeten JM, Bekker LG, Passmore JS, Heffron R, Jaspan HB, Happel AU.
    Front Immunol; 2021 Dec 20; 12():760504. PubMed ID: 34956191
    [Abstract] [Full Text] [Related]

  • 12. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Lancet; 2019 Jul 27; 394(10195):303-313. PubMed ID: 31204114
    [Abstract] [Full Text] [Related]

  • 13. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
    Smith JA, Beacroft L, Abdullah F, Buthelezi B, Makua M, Morroni C, Ramjee G, Velasquez C, Hallett TB.
    J Int AIDS Soc; 2020 Oct 27; 23(10):e25620. PubMed ID: 33030312
    [Abstract] [Full Text] [Related]

  • 14. Association of endogenous progesterone levels in young women using hormonal contraception with recent HIV-1 infection.
    Boodhram R, Moodley D, Abbai N, Ramjee G.
    BMC Womens Health; 2019 May 08; 19(1):63. PubMed ID: 31068152
    [Abstract] [Full Text] [Related]

  • 15. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa.
    Smit J, Gray A, McFadyen L, Zuma K.
    BMC Health Serv Res; 2001 May 08; 1():4. PubMed ID: 11401729
    [Abstract] [Full Text] [Related]

  • 16. Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1.
    Quispe Calla NE, Vicetti Miguel RD, Torres AR, Trout W, Gabriel JM, Hatfield AM, Aceves KM, Kwiek JJ, Kaur B, Cherpes TL.
    Immunohorizons; 2020 Feb 11; 4(2):72-81. PubMed ID: 32047094
    [Abstract] [Full Text] [Related]

  • 17. The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial.
    Avenant C, Singata-Madliki M, Bick AJ, Africander D, Balakrishna Y, Storbeck KH, Moliki JM, Dlamini S, Skosana S, Smit J, Beksinska M, Beesham I, Seocharan I, Batting J, Hofmeyr GJ, Hapgood JP.
    PLoS One; 2024 Feb 11; 19(8):e0307736. PubMed ID: 39178280
    [Abstract] [Full Text] [Related]

  • 18. Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception.
    Beksinska ME, Smit JA, Kleinschmidt I, Farley TM.
    S Afr Med J; 2011 Feb 11; 101(2):131-5. PubMed ID: 21678742
    [Abstract] [Full Text] [Related]

  • 19. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
    Beksinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F.
    Contraception; 2005 Mar 11; 71(3):170-5. PubMed ID: 15722065
    [Abstract] [Full Text] [Related]

  • 20. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception.
    Beksinska ME, Smit JA, Kleinschmidt I, Milford C, Farley TM.
    Contraception; 2010 Jan 11; 81(1):30-4. PubMed ID: 20004270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.